Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks immune response in lung cancer patients after standard treatment

NCT ID NCT06634199

Knowledge-focused Sponsor: Fundación GECP Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This observational study follows 50 people with stage III non-small cell lung cancer who have already received chemo-radiotherapy and are about to start immunotherapy with durvalumab. Researchers will look at how the immune system responds and whether that relates to survival. The goal is to learn more about real-world outcomes, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Durvalumab (Imfinzi)
What this could lead to
If successful, this study could help doctors understand which patients benefit most from immunotherapy after chemo-radiotherapy for stage III lung cancer.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients due to the small size and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Real world non-small cell lung cancer (NSCLC) stage IIIA/B and IIIC; PD-L1\>1%; non-resectable patients in treatment with IO after concurrent chemo-radiotherapy without progression.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histologically- or cytologically- documented NSCLC who present unresectable stage IIIA-IIIB-IIIC disease, according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology). * ECOG 0-1. * PDL1\>1%. * Age ≥ 18 years at time of study * Patients without progression after cCRT, that are going to receive IO treatment (Durvalumab) for 12 months as subsequent treatment as per standard clinical practice * Patient capable of proper therapeutic compliance and accessible for correct follow-up. * Patients must have signed, dated and IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines. Exclusion Criteria: * Patients who refuse to sign and date an IRB/IEC-approved written informed consent form. * No possibility of venipuncture * Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (stage III) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer (stage III) PDL1 gene mutation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    22 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complejo Hospitalario Universitario Del Ferrol

    RECRUITING

    Ferrol, A Coruña, 15405, Spain

  • Complexo Hospitalario Universitario De Vigo

    RECRUITING

    Vigo, Vigo, 36204, Spain

  • Hospital Clínico San Carlos

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • Hospital Clínico Universitario de Valladolid

    RECRUITING

    Valladolid, Valladolid, 47003, Spain

  • Hospital De Basurto

    RECRUITING

    Bilbao, Bilbao, 48013, Spain

  • Hospital General Universitario de Alicante

    RECRUITING

    Alicante, Alicante, 03010, Spain

  • Hospital General Universitario de Ciudad Real

    RECRUITING

    Ciudad Real, Ciudad Real, 13005, Spain

  • Hospital Universitari Vall d' Hebron

    RECRUITING

    Barcelona, Barcelona, 08035, Spain

  • Hospital Universitari de Gran Canària Doctor Negrín

    RECRUITING

    Las Palmas de Gran Canaria, Las Palmas, 35010, Spain

  • Hospital Universitario Central De Asturias

    RECRUITING

    Oviedo, Oviedo, 33011, Spain

  • Hospital Universitario De La Princesa

    RECRUITING

    Madrid, Madrid, 28006, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • Hospital Universitario La Paz

    RECRUITING

    Madrid, Madrid, 28046, Spain

  • Hospital Universitario Lucus Augusti

    RECRUITING

    Lugo, Lugo, 27003, Spain

  • Hospital Universitario Nuestra Señora de Candelaria

    RECRUITING

    Santa Cruz de Tenerife, Santa Cruz de Tenerife, 38010, Spain

  • Hospital Universitario Puerta de Hierro

    RECRUITING

    Majadahonda, Madrid, 28222, Spain

  • Hospital Universitario Y Politécnico La Fe

    RECRUITING

    Valencia, Valencia, 46026, Spain

  • Hospital Virgen del Rocio

    RECRUITING

    Seville, Sevilla, 41013, Spain

  • Hospital de la Santa Creu i Sant Pau

    RECRUITING

    Barcelona, Barcelona, 08041, Spain

  • Hospitalario Universitario A Coruña

    RECRUITING

    A Coruña, La Coruña, 15006, Spain

  • ICO Badalona, Hospital Germans Trias i Pujol

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • ICO Girona, Hospital Josep Trueta

    RECRUITING

    Girona, Girona, 17007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.